Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced financial results for the fourth ...
Recent Phase 2 topline results demonstrate NS002’s potential for best-in-class epinephrine delivery, with statistically significant improvements ...
Good evening, and welcome to Phreesia's Earnings Conference Call for the Fourth Quarter of Fiscal 2026, which ended on January 31, 2026. Joining me on today's call is Chaim Indig, our Chief Executive ...
Executives from Eyepoint Pharmaceuticals (NASDAQ:EYPT) told investors at RBC Capital Markets’ Ophthalmology Conference that ...
VolitionRx Limited (AMEX:VNRX) Q4 2025 Earnings Call Transcript April 1, 2026 Operator: Good morning, ladies and gentlemen, ...
Company has already submitted proposed confirmatory trial for FDA review, as required under accelerated approval pathway Company plans to submit ...
Despite ongoing debate, medications such as Ozempic continue to rank among the most commonly prescribed treatments for weight ...
Migraines are one of the leading causes of disability worldwide, but are often dismissed as stress or ‘just a headache’ — a ...
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Q4 2025 Earnings Call Transcript March 24, 2026 LENZ Therapeutics, Inc. misses on ...
Longeveron Inc. (NASDAQ:LGVN) Q4 2025 Earnings Call Transcript March 17, 2026 Longeveron Inc. beats earnings expectations.
No, this is not a sermon or reflection on my years in Sunday school. However, it does provide a glimpse into many of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results